EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer

Peter Schmid, Javier Cortes, Rebecca Dent, Heather McArthur, Lajos Pusztai, Sherko Kümmel, Carsten Denkert, Yeon Hee Park iD, Rina Hui, Nadia Harbeck, Masato Takahashi, Seock-Ah Im und 12 weitere

New England Journal of Medicine · 28.11.2024 · 391 (21) · 1981-1991

DOI: 10.1056/nejmoa2409932 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 28.11.2024. Verfasst von Peter Schmid und 23 weiteren Autor:innen. Beteiligte Einrichtung: From the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer…. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Antineoplastic Combined Chemotherapy Protocols, Neoadjuvant Therapy, Neoplasm Staging. Die Arbeit wurde bisher 638-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Merck, Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsNeoadjuvant TherapyNeoplasm StagingTriple Negative Breast NeoplasmsAgedFemaleHumansMiddle AgedAntineoplastic Agents, ImmunologicalCarboplatinChemotherapy, AdjuvantCyclophosphamideEpirubicinKaplan-Meier EstimatePaclitaxelSurvival AnalysisTreatment OutcomeDouble-Blind Method

Substanzen

Antibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalCarboplatinCyclophosphamideEpirubicinPaclitaxelpembrolizumab

Autor:innen und Institutionen

  • From the Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University of London, London (P.S.); International Breast Cancer Center, Pangaea Oncology, Quirónsalud Group, and Medical Scientia Inn…

ORCID-Profile: Yeon Hee Park, Theodoros Foukakis

Förderung

  • Merck
  • Merck & Co., Inc.

Zitieren

APA

Schmid, P., Cortes, J., Dent, R., McArthur, H., Pusztai, L., Kümmel, S., Denkert, C., Park, Y. H., Hui, R., Harbeck, N., Takahashi, M., Im, S. A., Untch, M., Fasching, P. A., Mouret-Reynier, M. A., Foukakis, T., Ferreira, M., Cardoso, F., Zhou, X., …, & KEYNOTE-522 Investigators (2024). Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine, 391(21), 1981-1991. https://doi.org/10.1056/nejmoa2409932

Vancouver

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S, et al. Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer. New England Journal of Medicine. 2024;391(21):1981-1991. doi:10.1056/nejmoa2409932

BibTeX
@article{Schmid2024,
  author = {Schmid, Peter and Cortes, Javier and Dent, Rebecca and McArthur, Heather and Pusztai, Lajos and Kümmel, Sherko and Denkert, Carsten and Park, Yeon Hee and Hui, Rina and Harbeck, Nadia and Takahashi, Masato and Im, Seock-Ah and Untch, Michael and Fasching, Peter A and Mouret-Reynier, Marie-Ange and Foukakis, Theodoros and Ferreira, Marta and Cardoso, Fatima and Zhou, Xuan and Karantza, Vassiliki and Tryfonidis, Konstantinos and Aktan, Gursel and O'Shaughnessy, Joyce and KEYNOTE-522 Investigators, KEYNOTE-522 Investigators},
  title = {Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer},
  journal = {New England Journal of Medicine},
  year = {2024},
  volume = {391},
  number = {21},
  pages = {1981--1991},
  doi = {10.1056/nejmoa2409932}
}
Kostenlos starten →